HOUSTON--(BUSINESS WIRE)--BayPoint Biosystems Inc., a privately held personalized medicine company, announced today that it has entered into a technology licensing agreement with the University of Texas M. D. Anderson Cancer Center. Under the terms of the agreement, BayPoint obtains exclusive, worldwide commercial rights to certain proteomic technologies as well as clinical biomarkers that predict therapeutic response for certain ovarian and breast cancers. “This strategic licensing agreement will further enable BayPoint to bring innovative personalized medicine products to the ovarian and breast cancer markets,” explained James Erickson, founder, president and Chief Executive Officer of BayPoint. “The application of this technology also provides our pharmaceutical partners with new insights into how their drugs are working, in which cancers their drugs are most likely to be effective and how to rationally combine experimental drugs with approved therapeutics.”
